Gene expression signatures that predict outcome of tamoxifen-treated estrogen receptor-positive, high-risk, primary breast cancer patients: a DBCG study.

<h4>Background</h4>Tamoxifen significantly improves outcome for estrogen receptor-positive (ER+) breast cancer, but the 15-year recurrence rate remains 30%. The aim of this study was to identify gene profiles that accurately predicted the outcome of ER+ breast cancer patients who receive...

Full description

Bibliographic Details
Main Authors: Maria B Lyng, Anne-Vibeke Lænkholm, Qihua Tan, Werner Vach, Karina H Gravgaard, Ann Knoop, Henrik J Ditzel
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23342080/pdf/?tool=EBI